Effects of two different somatostatin analogs on glucose tolerance in acromegaly

C. Ronchi, P. Epaminonda, V. Cappiello, P. Beck-Peccoz, Maura Arosio

Research output: Contribution to journalArticlepeer-review


Impaired glucose tolerance is present in many acromegalic patients and treatment with somatostatin analogs has variable effects on glycemic control. The aim of this study was to compare the effects of 2 somatostatin analogs on glucose metabolism, lanreotide slow release (L-SR) and octreotide long acting release (O-LAR), in 10 patients with acromegaly (2 of whom with overt Type 2 diabetes mellitus). Glucose and insulin levels in fasting conditions and in response to OGTT, evaluated as AUC, insulin resistance (IR) evaluated by homeostatic model assessment (HOMA-IR), glycosylated hemoglobin (HbA1c), GH, IGF-I, were assessed during L-SR and O-LAR treatment. Mean fasting glucose, glucose response to OGTT and HbA1c levels in 8 non-diabetic patients did not significantly change after L-SR therapy while they all increased after O-LAR treatment (p

Original languageEnglish
Pages (from-to)502-507
Number of pages6
JournalJournal of Endocrinological Investigation
Issue number6
Publication statusPublished - 2002


  • Glucose metabolism
  • IGF-I
  • Insulin resistance
  • Lanreotide
  • Octreotide

ASJC Scopus subject areas

  • Endocrinology


Dive into the research topics of 'Effects of two different somatostatin analogs on glucose tolerance in acromegaly'. Together they form a unique fingerprint.

Cite this